Factor | n = 148 | % |
---|---|---|
Age (median 66 years) | ||
< 66 years | 73 | 49.3 |
≥ 66 years | 75 | 50.7 |
Gender | ||
Women | 95 | 64.2 |
Men | 53 | 35.8 |
Timing of CPM | ||
Synchronous CPM | 73 | 49.3 |
Metachronous CPM | 75 | 50.7 |
Location of primary tumour | ||
Rectum | 15 | 10.1 |
Left colon | 52 | 35.1 |
Right colon | 80 | 54.1 |
Data missing | 1 | 0.7 |
Preoperative laparotomy or laparoscopy | ||
Yes | 53 | 35.8 |
No | 95 | 64.2 |
Reason for prolonged time to decision for surgery | ||
Tumor investigation | 142 | 95.9 |
Medical investigation of patient factors | 1 | 0.7 |
Other | 5 | 3.4 |
Type of surgery | ||
CRS + HIPEC | 106 | 71.6 |
CRS | 13 | 8.8 |
Open-close | 29 | 19.6 |
HIPEC regime | ||
Oxaliplatin | 89 | 59.5 |
Irinotecan | 14 | 9.5 |
Mitomycin C | 3 | 2 |
PCI score | ||
PCI ≤ 20 | 102 | 68.9 |
PCI ≥ 21 | 40 | 27 |
Data missing | 6 | 4.1 |
Cytoreduction score | ||
CC0 | 106 | 71.6 |
CC1 | 11 | 7.4 |
CC2 | 1 | 0.7 |
CC3 | 29 | 19.6 |
Data missing | 1 | 0.7 |
Clavien-Dindo grade | ||
Grade I–II | 109 | 73.6 |
Grade III–IV | 37 | 25 |
Dead | 2 | 1.4 |
Liver metastases | ||
Yes | 16 | 10.8 |
No | 132 | 89.2 |
Signet ring cells | ||
Yes | 28 | 18.9 |
No | 118 | 79.7 |
Data missing | 2 | 1.4 |
BRAF mutation | ||
Yes | 10 | 6.8 |
No | 62 | 41.9 |
ND | 76 | 51.4 |
KRAS mutation | ||
Yes | 35 | 23.6 |
No | 38 | 25.7 |
ND | 75 | 50.7 |
Adjuvant treatment | ||
Yes | 58 | 39.2 |
No | 87 | 58.8 |
Data missing | 3 | 2 |